Skip to main content

Advertisement

SpringerLink
Log in

A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

The primary objective of this trial was to establish the maximum tolerated dose (MTD) of oxaliplatin 130 mg/m2 preceded by escalating doses of docetaxel 60 mg/m2 (75, 90, 100 mg/m2) administered every 3 weeks. A total of 11 patients were entered; 10 evaluable for response: 4 stable disease (liver, ovary and esophagus) and 1 partial remission (esophagus). At dose level 1, there was 1 dose-limiting toxicity (DLT) (grade 3 allergic reaction). At dose level 2, there were 3 DLTs (3 grade 4 neutropenia, grade 3 gastritis, diarrhea, hypophosphatemia, neuro-mood). The MTD is docetaxel 60 mg/m2 with oxaliplatin 130 mg/m2.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cvitkovic E (1998) Ongoing and unsaid on oxaliplatin: the hope. Br J Cancer 77(Suppl 4):8–11

    Article  PubMed  CAS  Google Scholar 

  2. Silvestro L, Anal H, Sommer F (1990) Comparative effects of a new platinum analog (trans-1-diamine-cyclohexane oxalato-platinum: L-OHP) with CDDP on various cells: correlation with intracellular accumulation. Proc Anticancer Res, pp Abstract # 115

  3. Pendyala L, Kidani Y, Perez R et al (1995) Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett 97:177–184

    Article  PubMed  CAS  Google Scholar 

  4. Extra JM, Espie M, Calvo F et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25:299–303

    Article  PubMed  CAS  Google Scholar 

  5. Extra JM, Marty M, Brienza S et al (1998) Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 25:13–22

    PubMed  CAS  Google Scholar 

  6. Synold TW, Takimoto CH, Doroshow JH et al (2007) Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res 13:3660–3666

    Article  PubMed  CAS  Google Scholar 

  7. Morgan RJ Jr, Doroshow JH, Synold T et al (2003) Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 9:5896–5901

    PubMed  CAS  Google Scholar 

  8. Kouroussis C, Agelaki S, Mavroudis D et al (2003) A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer. Anticancer Res 23:785–791

    PubMed  CAS  Google Scholar 

  9. Kim KH, Park YS, Chang MH, Kim HS, Jun HJ, Uhm J, Yi SY, Lim do H, Ji SH, Park MJ, Lee J, Park SH, Park JO, Lim HY, Kang WK (2009) A phase I/II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer. Cancer Chemother Pharmacol 64(2):347–353. doi:10.1007/s00280-008-0878-4

    Google Scholar 

Download references

Acknowledgments

Supported in part by Grants No. U01CA062505, P30CA033572 and P30CA14089 from the National Institutes of Health.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. USC/Norris Comprehensive Cancer Center, Oncology, Los Angeles, CA, USA

    Syma Iqbal, Heinz-Josef Lenz & Susan Groshen

  2. University of California, Davis, Sacramento, CA, USA

    David R. Gandara

  3. City of Hope, Oncology, Los Angeles, CA, USA

    Stephen I. Shibata, Timothy W. Synold & Edward M. Newman

Authors
  1. Syma Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heinz-Josef Lenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David R. Gandara
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stephen I. Shibata
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Susan Groshen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Timothy W. Synold
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Edward M. Newman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Syma Iqbal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iqbal, S., Lenz, HJ., Gandara, D.R. et al. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 72, 85–91 (2013). https://doi.org/10.1007/s00280-013-2171-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-013-2171-4

Keywords

Search

Navigation